UNIGE document Scientific Article
previous document  unige:25168  next document
add to browser collection
Title

High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus

Authors
Ferry, Tristan
show hidden authors show all authors [1 - 11]
Published in Antimicrobial agents and chemotherapy. 2012, vol. 56, no. 3, p. 1258-64
Abstract Reduced susceptibility to glycopeptides in methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates is considered a risk factor for failure of glycopeptide therapy. We compared the prevalences of MRSA isolates with reduced glycopeptide susceptibility in patients with versus without persistent or recurrent MRSA bloodstream infections. A retrospective cohort study at the University Hospital of Geneva identified 27 patients with persistent or recurrent clonally related MRSA bacteremic episodes over an 8-year period, which included 208 consecutive nosocomial MRSA bacteremic episodes. Vancomycin and teicoplanin MICs were determined by a modified macrodilution assay allowing improved detection of glycopeptide-intermediate MRSA isolates (GISA), characterized by elevated teicoplanin or/and vancomycin MICs (≥ 4 μg/ml). For 16 patients (59%), their pretherapy and/or posttherapy MRSA isolates showed elevated teicoplanin MICs, among which 10 (37%) concomitantly displayed elevated vancomycin MICs. In contrast, 11 other patients (41%) were persistently or recurrently infected with non-GISA isolates. In comparison, only 39 (22%) of 181 single isolates from patients with no microbiological evidence of persistent or recurrent infections showed elevated teicoplanin MICs, among which 14 (8%) concomitantly displayed elevated vancomycin MICs. Clinical, microbiological, and pharmacokinetic variables for patients persistently or recurrently infected with GISA or non-GISA isolates were similar. Bacteremic patients with a poor response to glycopeptide therapy had a 2.8-fold- and 4.8-fold-higher rates of MRSA isolates displaying elevated teicoplanin and vancomycin MICs, respectively, than patients with single isolates (P < 0.0001). Detection of elevated teicoplanin MICs may help to predict a poor response to glycopeptide therapy in MRSA bacteremic patients.
Keywords AgedAged, 80 and overAnti-Bacterial Agents/pharmacology/therapeutic useBacteremia/drug therapy/microbiologyChild, PreschoolDrug Resistance, Bacterial/drug effectsFemaleHumansMaleMethicillin-Resistant Staphylococcus aureus/drug effects/growth & development/isolation & purificationMicrobial Sensitivity TestsMiddle AgedRecurrenceRetrospective StudiesStaphylococcal Infections/drug therapy/microbiologyTeicoplanin/pharmacology/therapeutic useVancomycin/pharmacology/therapeutic use
Identifiers
PMID: 22155824
Full text
Article (Published version) (168 Kb) - document accessible for UNIGE members only Limited access to UNIGE
Structures
Research groups Analyse génomique et fonctionnelle du staphylocoque doré (604)
Epidémiologie et contrôle de la résistance aux antibiotiques (866)
Glycopeptide résistance (28)
Citation
(ISO format)
UCKAY, Ilker et al. High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus. In: Antimicrobial agents and chemotherapy, 2012, vol. 56, n° 3, p. 1258-64. doi: 10.1128/AAC.05808-11 https://archive-ouverte.unige.ch/unige:25168

461 hits

0 download

Update

Deposited on : 2013-01-09

Export document
Format :
Citation style :